Literature DB >> 31305354

Outcome of Patients Treated With Porous Tantalum Acetabular Implants for Neoplastic Periacetabular Lesions.

Matthew T Houdek1, Matthew P Abdel, Kevin I Perry, Ahmet Salduz, Peter S Rose, Franklin H Sim, David G Lewallen.   

Abstract

INTRODUCTION: The periacetabular region is a common location for nonprimary neoplastic tumors. Although these tumors were historically treated with a cemented acetabular implant, we previously reported on the short-term follow-up on the use of a tantalum acetabular shell to reconstruct these defects. This study expands our previous report on longer follow-up, with specific emphasis on patient and implant survivorship, radiographic results, and clinical outcomes.
METHODS: Fifty-eight patients (32 women and 26 men) were treated using a tantalum acetabular implant and total hip arthroplasty to reconstruct a nonprimary neoplastic process between 2001 and 2014. The mean age and body mass index were 62 years and 28 kg/m, respectively. The most common diagnosis was metastatic disease (n = 29). The patients' medical records and radiographs were reviewed to assess Harris hip scores and radiographic fixation. The mean follow-up for surviving patients was 8 years.
RESULTS: At the most recent follow-up, 41 patients were dead of the disease and 17 were alive with the disease and no cases of acetabular implant revision were reported. Two patients had a progressive radiolucent line; however, they also had radiographic evidence of local disease progression. After reconstruction, patients had a significant (P = 0.0001) increase in their Harris hip score (37 vs. 72). DISCUSSION: In patients with periacetabular metastatic diseases and hematologic malignancies treated with total hip arthroplasty, a highly porous tantalum revision-type shell fixed with multiple screws, and supplemental support with acetabular augments or cup-cage reinforcement, can successfully provide patients with a stable, well-fixed, and durable construct, with no cases of mechanical failure at mid-term follow-up.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31305354     DOI: 10.5435/JAAOS-D-18-00482

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  6 in total

1.  Augmenting Pathologic Acetabular Bone Loss With Photodynamic Nails to Support Primary Total Hip Arthroplasty.

Authors:  Marilyn Heng; Mitchell S Fourman; Aiden Mitrevski; Emily Berner; Santiago A Lozano-Calderon
Journal:  Arthroplast Today       Date:  2022-10-11

2.  Feasibility and preliminary efficacy of tantalum components in the management of acetabular reconstruction following periacetabular oncologic resection in primary malignancies.

Authors:  Pengfei Zan; Xiaojun Ma; Hongsheng Wang; Zhengdong Cai; Jiakang Shen; Wei Sun
Journal:  Eur J Med Res       Date:  2022-08-17       Impact factor: 4.981

Review 3.  Outcomes of Hip Reconstruction for Metastatic Acetabular Lesions: A Scoping Review of the Literature.

Authors:  Sandeep Krishan Nayar; Thomas A Kostakos; Olga Savvidou; Konstantinos Vlasis; Panayiotis J Papagelopoulos
Journal:  Curr Oncol       Date:  2022-05-26       Impact factor: 3.109

4.  Emerging Concepts in the Surgical Management of Peri-Acetabular Metastatic Bone Disease.

Authors:  Aaron Gazendam; Daniel Axelrod; David Wilson; Michelle Ghert
Journal:  Curr Oncol       Date:  2021-07-17       Impact factor: 3.677

5.  Comparison of Porous Tantalum Acetabular Implants and Harrington Reconstruction for Metastatic Disease of the Acetabulum.

Authors:  Matthew T Houdek; Peter C Ferguson; Matthew P Abdel; Anthony M Griffin; Mario Hevesi; Kevin I Perry; Peter S Rose; Jay S Wunder; David G Lewallen
Journal:  J Bone Joint Surg Am       Date:  2020-07-15       Impact factor: 6.558

6.  Comparison of the Primary Stability of Porous Tantalum and Titanium Acetabular Revision Constructs.

Authors:  Nicholas A Beckmann; Rudi G Bitsch; Mareike Schonhoff; Klaus-Arno Siebenrock; Martin Schwarze; Sebastian Jaeger
Journal:  Materials (Basel)       Date:  2020-04-10       Impact factor: 3.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.